Who Exports Sodium from India — 985 Suppliers Behind a $361.2M Market
India's sodium export market is supplied by 985 active exporters who collectively shipped $361.2M across 15,000 shipments. EUGIA PHARMA SPECIALITIES LIMITED leads with a 9.1% market share, followed by GLAND PHARMA LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 34.6% of total export value, reflecting a moderately competitive market structure.
Top Sodium Exporters from India — Ranked by Export Value
EUGIA PHARMA SPECIALITIES LIMITED is the leading sodium exporter from India, holding a 9.1% share of the $361.2M market across 15,000 shipments from 985 exporters. The top 5 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, GLAND PHARMA LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, CIPLA LIMITED, AUROBINDO PHARMA LTD — collectively control 34.6% of total export value, indicating a competitive market. Individual shares are: EUGIA PHARMA SPECIALITIES LIMITED (9.1%), GLAND PHARMA LIMITED (8.9%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (6.8%), CIPLA LIMITED (6.1%), AUROBINDO PHARMA LTD (3.7%).
Top Sodium Exporters from India
Ranked by export value · 985 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | EUGIA PHARMA SPECIALITIES LIMITED RABERPRAZOLE SODIUM DELAYED RELEASE TABLETS 20MG,51000441 - ENOXAPARIN SODIUM INJECTION,51000440 - ENOXAPARIN SODIUM INJECTION, | $32.9M | 2 | 9.1% |
| 2 | GLAND PHARMA LIMITED DEXAMETHASONE SODIUM PHOSPHATE INJECTIONDIVALPROEX SODIUM EXTENDED RELEASE TABLEHUMAN MEDICINES-SODIUM CHLORIDE INTRAVEN | $32.1M | 21 | 8.9% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED DICLOFENAC SODIUM WITH PARACETAMOL TABLEDEXAMETHASONE SODIUM PHOSPHATE INJECTIONDIVALPROEX SODIUM EXTENDED RELEASE TABLE | $24.6M | 18 | 6.8% |
| 4 | CIPLA LIMITED DEXAMETHASONE SODIUM PHOSPHATE INJECTIONHUMAN MEDICINES-SODIUM CHLORIDE INTRAVENDOLUTEGRAVIR + LAMIVUDINE +T | $22.2M | 23 | 6.1% |
| 5 | AUROBINDO PHARMA LTD DICLOFENAC SODIUM WITH PARACETAMOL TABLEDIVALPROEX SODIUM EXTENDED RELEASE TABLEHYDROCORTISONE SODIUM SUCCINATE FOR INJE | $13.2M | 10 | 3.7% |
| 6 | UNICHEM LABORATORIES LIMITED SODIUM CHLORIDE INTRAVENOUS INFUSION 0.9SODIUM CHLORIDE INTRAVENOUS INFUSION 0.9% 1000MLSODIUM CHLORIDE INTRAVENOUS INFUSION BP1000ML | $13.0M | 2 | 3.6% |
| 7 | MYLAN LABORATORIES LIMITED DIVALPROEX SODIUM EXTENDED RELEASE TABLERABERPRAZOLE SODIUM DELAYED RELEASE TABLETS 20MG,51000441 - ENOXAPARIN SODIUM INJECTION, | $12.5M | 8 | 3.5% |
| 8 | DR.REDDY'S LABORATORIES LTD DIVALPROEX SODIUM EXTENDED RELEASE TABLEENCORATE TABLETS 200MG (SODIUM VALPROATERABERPRAZOLE SODIUM DELAYED RELEASE TABLETS 20MG, | $10.4M | 5 | 2.9% |
| 9 | TROIKAA PHARMACEUTICALS LIMITED DICLOFENAC SODIUM WITH PARACETAMOL TABLEHYDROCORTISONE SODIUM SUCCINATE FOR INJEDOLUTEGRAVIR + LAMIVUDINE +T | $10.2M | 27 | 2.8% |
| 10 | MACLEODS PHARMACEUTICALS LTD DICLOFENAC SODIUM WITH PARACETAMOL TABLEDEXAMETHASONE SODIUM PHOSPHATE INJECTIONHUMAN MEDICINES-SODIUM CHLORIDE INTRAVEN | $10.0M | 31 | 2.8% |
| 11 | ENCUBE ETHICALS PRIVATE LIMITED | $9.8M | 1 | 2.7% |
| 12 | TORRENT PHARMACEUTICALS LTD DICLOFENAC SODIUM WITH PARACETAMOL TABLEDIVALPROEX SODIUM EXTENDED RELEASE TABLEHYDROCORTISONE SODIUM SUCCINATE FOR INJE | $8.5M | 22 | 2.4% |
| 13 | MACLEODS PHARMACEUTICALS LIMITED DICLOFENAC SODIUM WITH PARACETAMOL TABLEDEXAMETHASONE SODIUM PHOSPHATE INJECTIONHUMAN MEDICINES-SODIUM CHLORIDE INTRAVEN | $8.0M | 12 | 2.2% |
| 14 | FRESENIUS KABI INDIA PRIVATE LIMITED DEXAMETHASONE SODIUM PHOSPHATE INJECTIONHUMAN MEDICINES-SODIUM CHLORIDE INTRAVENSODIUM CHLORIDE INTRAVENOUS INFUSION 0.9 | $7.8M | 17 | 2.1% |
| 15 | BIOLOGICAL E. LIMITED ENCORATE TABLETS 200MG (SODIUM VALPROATERABERPRAZOLE SODIUM DELAYED RELEASE TABLETS 20MG,ENCORATE CHRONO 200MG TABLETS (SODIUM VA | $5.7M | 2 | 1.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Sodium exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| EUGIA PHARMA SPECIALITIES LIMITED | Warning Letter, August 20 | Unknown | Unknown | Not verified | FDA issued a warning letter citing CGMP violations at Unit III facility. |
| AUROBINDO PHARMA LTD | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
| CIPLA LIMITED | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
| DR. REDDY'S LABORATORIES LTD | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
| GLAND PHARMA LIMITED | Approved | Unknown | Unknown | Multiple | Holds several FDA-approved ANDAs. |
| MACLEODS PHARMACEUTICALS LTD | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
| TORRENT PHARMACEUTICALS LTD | Approved | Unknown | Unknown | Multiple | Holds several FDA-approved ANDAs. |
| FRESENIUS KABI INDIA PRIVATE LIMITED | Approved | Yes | Unknown | Multiple | WHO prequalified multiple products; holds several FDA-approved ANDAs. (extranet. |
TransData Nexus reviewed the regulatory standing of 10 leading Sodium exporters from India. 9 hold US FDA facility approvals, 7 maintain WHO-GMP certification, and 0 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Sodium sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts leading exporters such as EUGIA PHARMA SPECIALITIES LIMITED and GLAND PHARMA LIMITED, which have reported exports of $32.9 million (9.1%) and $32.1 million (8.9%) respectively. This concentration underscores Hyderabad's pivotal role in the sodium-based pharmaceutical supply chain.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Companies like SUN PHARMACEUTICAL INDUSTRIES LIMITED and CIPLA LIMITED, with exports of $24.6 million (6.8%) and $22.2 million (6.1%) respectively, are headquartered here. Their substantial export figures reflect the region's expertise in producing finished dosage forms of sodium-based medications.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway, leveraging its proximity to major ports. This region facilitates the global distribution of pharmaceutical products, including those from companies like AUROBINDO PHARMA LTD and UNICHEM LABORATORIES LIMITED, which have reported exports of $13.2 million (3.7%) and $13.0 million (3.6%) respectively. The strategic location enhances the efficiency of exporting sodium-based pharmaceuticals to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, largely due to favorable tax incentives. This region attracts numerous pharmaceutical companies, contributing to the production and export of various formulations, including sodium-based products.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Leverage Cluster Specializations: Source APIs from Hyderabad and formulations from Ahmedabad-Vadodara to capitalize on regional expertise.
- Optimize Logistics: Utilize the Mumbai-Thane-Raigad region's export infrastructure to streamline shipping processes.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity.
By strategically sourcing from these specialized clusters, companies can enhance the reliability and efficiency of their sodium-based pharmaceutical supply chains.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Sodium exporters from India
EUGIA PHARMA SPECIALITIES LIMITED — Eugia Pharma launches generic Pomalidomide Capsules in the US
Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, launched Pomalidomide Capsules (1 mg, 2 mg, 3 mg, and 4 mg) in the US market. This product is the generic equivalent of Pomalyst Capsules by BMS Pharmaceuticals Corp.
Impact: This launch is expected to enhance Eugia's revenue streams, potentially increasing their sodium export capacity.
SUN PHARMACEUTICAL INDUSTRIES LIMITED — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma acquired Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million.
Impact: This acquisition may lead to a diversification of Sun Pharma's product portfolio, potentially affecting their focus on sodium exports.
CIPLA LIMITED — Cipla acquires Ivia Beaute's cosmetics business for ₹130 crore
Cipla acquired the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore.
Impact: This acquisition indicates Cipla's diversification into the cosmetics sector, which may influence their resource allocation and sodium export activities.
Common Questions — Sodium Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which sodium supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, EUGIA PHARMA SPECIALITIES LIMITED leads with 271 recorded shipments worth $32.9M. GLAND PHARMA LIMITED (229 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (309 shipments) are also established high-volume exporters.
Q How many sodium manufacturers are there in India?
India has 985 active sodium exporters with a combined export market of $361.2M across 15,000 shipments to 177 countries. The top 5 suppliers hold 34.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for sodium from India?
Average FOB unit price: $31.25 per unit, ranging from $0.00 to $61483.79. Average shipment value: $24.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 985 verified Indian exporters of Sodium ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 15,000 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 177 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
15,000 Verified Shipments
985 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists